TEGOPAC® RD are silane-modified polymers with lateral cross-linking functions which release ethanol during the curing process. TEGOPAC® RD can be used to decrease viscosity of adhesives & sealant formulations or to develop non-staining adhesives & sealant products
The upcoming product family will consist of two reactive diluents which differ in cross-linking properties.
Within different market segments and applications (e.g. flooring adhesives, assembly adhesives, roof sealing) customers can benefit from a variety of properties:
• Decrease of formulation & polymer viscosity
• Improvement of cure-through properties
• Increase of hardness & tensile strength
• Development of methanol-free formulations is possible
• TEGOPAC® RD can be combined with different types of silane-modified polymers
TEGOPAC® RD can be used instead of standard plasticizers in adhesives & sealant formulations to avoid migration effects.
TEGOPAC® RD can be blended with different types of silane-modified polymers and epoxy polymers. Formulating with various plasticizers, fillers, and other additives is possible to address applications like parquet adhesives, roof sealing applications or pressure sensitive adhesives and many more…
TEGOPAC® RD will strengthen Evonik Nutrition & Care’s position as a solution provider for various needs in the adhesive & sealants market and enhance the silane-modified polymer portfolio.
TEGOPAC® RD will be available in America during the year 2016.
About Nutrition & Care
The Nutrition & Care segment is led by Evonik Nutrition & Care GmbH and contributes to fulfilling basic human needs. That includes applications for everyday consumer goods as well as animal nutrition and health care. This segment employed about 7,000 employees, and generated sales of around €4.2 billion in 2014.
Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals, operating in the Nutrition & Care, Resource Efficiency and Performance Materials segments. The company benefits from its innovative prowess and integrated technology platforms. In 2014 more than 33,000 employees generated sales of around €12.9 billion and an operating profit (adjusted EBITDA) of about €1.9 Billion.
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.